Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma

The FDA approved lirafugratinib as the third FGFR2 inhibitor for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, targeting FGFR2 fusion-positive disease and designed to overcome resistance mutations.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.